Drug intelligence / Profile preview

human rotavirus, live attenuated-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis

Development stage: Approved
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral

Overview

human rotavirus, live attenuated-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis refers to a clinical trial regimen involving the concomitant administration of a live-attenuated human rotavirus vaccine (Rotarix) and the SHAN6 hexavalent vaccine (DTwP-HepB-Hib-IPV). SHAN6 is a fully liquid, ready-to-use vaccine developed by Sanofi Healthcare India that combines diphtheria toxoid, tetanus toxoid, whole-cell pertussis (wP), hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b (Hib) conjugate, and inactivated poliovirus (IPV) antigens. This combination is designed to provide comprehensive protection against seven major pediatric infectious diseases. The regimen was evaluated in a Phase 3 clinical trial (NCT04429295) in Thailand to assess its immunogenicity and safety when given alongside other routine pediatric vaccines, such as the 13-valent pneumococcal conjugate vaccine (Prevnar 13).

Brand names: SHAN6SHAN-6SHAN 6Rotarix
Other names: DTwP-HepB-Hib-IPV + Rotavirus vaccineSHAN6 + Rotarix

Targets

RVA (Rotavirus A)

Beyond the preview

Go deeper on human rotavirus, live attenuated-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human rotavirus, live attenuated-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussis.

Explore the full profile